Delivery Order SPE2DB24D8002-SPE2DB25FJNMP
Award Date
4/9/25
Potential Completion Date
4/10/25
Potential Value
$3.4K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $4,206.61, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of 4566601984 units of the pharmaceutical product Fluticasone-Salmeterol 115-21 12GM, a respiratory medication used to treat asthma and chronic obstructive pulmonary disease (COPD). The contract has a firm fixed-price delivery order structure and an ultimate completion date of December 4, 2024....
This is a federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, by the Defense Logistics Agency (DLA). The $6,172.15 firm fixed-price delivery order contract is for the supply of Fluticasone-Salmeterol 230-21 12GM, a respiratory medication, to the DLA. This award is part of Dakota Drug, Inc.'s larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, which allows the company to provide a wide...
This is a $6,331.52 firm-fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of fluticasone-salmeterol 230-21 12GM, a pharmaceutical product, with a performance period ending on January 15, 2025. Dakota Drug, Inc. holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA as part of the ECAT Generation V Program, which allows the company to...
This federal contract award, valued at $3,381.49, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business located in Anoka, Minnesota. The contract is for the delivery of Fluticasone-Salmeterol 115-21 12GM, a respiratory medication, with a completion date of May 8, 2025. Dakota Drug, Inc. holds a significant Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, as part of the DLA Troop Support Medical's ECAT...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $3,317.13, is for the delivery of the pharmaceutical product Fluticasone-Salmeterol 115-21 12GM. The contract has an ultimate completion date of February 25, 2025. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, SPE2DB24D8001, valued at $999,999,999.00, as...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business that specializes in providing pharmaceutical products, medical supplies, and healthcare equipment to the U.S. federal government. The contract, valued at $7,225.70, is a firm fixed-price delivery order for the supply of Fluticasone-Salmeterol 115-21 12GM inhalers. The award is associated with a larger Indefinite Delivery Contract (IDC) between Dakota...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $3,476.84, is for the delivery of Fluticasone-Salmeterol 45-21 12GM, a pharmaceutical product. The contract does not have a set-aside designation and is set to be completed by October 29, 2024. Dakota Drug, Inc. is a key supplier to the DLA Troop Support Medical division, providing a range of pharmaceutical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $2,437.20 firm fixed-price delivery order contract is for the supply of Fluticasone-Salmeterol 115-21 12GM, a pharmaceutical product. The contract has an ultimate completion date of June 3, 2024. Dakota Drug, Inc. is an established vendor in the federal medical supply market, holding a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $2,850.10, is for the delivery of Fluticasone-Salmeterol 230-21 12GM inhalers. The contract has a firm fixed-price pricing type and a completion date of April 10, 2025. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, as part of the DLA Troop Support Medical's ECAT...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $2,553.05, is for the delivery of Fluticasone-Salmeterol 230-21 12GM, a respiratory medication, to support U.S. Armed Forces medical operations. The contract is a firm fixed-price, non-set-aside award with a completion date of January 28, 2025. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract...